high mobility group nucleosome binding domain 1 pseudogene 30Genealiases: []
Q-omics provides the consensus-scored HMGN1P30 profile across patient tissues and cancer cell-line models. HMGN1P30 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HMGN1P30 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, HMGN1P30 RNA expression shows 7,914 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight MESO, BLCA, and KICH as cancer lineages where HMGN1P30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN1P30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN1P30 survival associations across molecular data types. HMGN1P30 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN1P30 RNA expression–survival associations across cancer types. High HMGN1P30 expression shows unfavorable associations in MESO, LIHC and READ, but favorable associations in STAD, BLCA and GBM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for HMGN1P30 RNA expression.
This table summarizes HMGN1P30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN1P30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN1P30 shows lower tumor expression in THCA and higher tumor expression in BLCA, LUAD, BRCA, LUSC and ESCA. The BLCA box plot shows higher HMGN1P30 RNA expression in tumor versus normal tissue (log2 FC = +0.275, t-test p = .001).
This table shows molecular features associated with HMGN1P30 in patient tissues and cancer cell lines. In patient samples, HMGN1P30 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set.
